CoreCap Advisors’s Aquestive Therapeutics AQST Stock Holding History

CoreCap Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-183	Closed	-$531	–	2785
2025 Q1	$531	Buy	+183	New	+$554	﹤0.01%	2673

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CoreCap Advisors's AQST Position: Q2 2025 in Review

CoreCap Advisors sold out of Aquestive Therapeutics (AQST) in Q2 2025, closing a stake of 183 shares — an estimated $531 sold.

CoreCap Advisors first reported a position in AQST in Q1 2025 and held it in 1 quarter. The position peaked at $531 in Q1 2025. 116 funds tracked by Wall St. Rank hold AQST as of Q2 2025.

CoreCap Advisors reported no remaining Aquestive Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 183 Aquestive Therapeutics shares in Q2 2025, an estimated $531.
CoreCap Advisors first reported a position in Aquestive Therapeutics in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Aquestive Therapeutics position peaked at $531 in Q1 2025.
116 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.